Clene will join APST Research to explore how CNM-Au8 affects NfL levels in ALS patients treated in expanded access programs.

SALT LAKE CITY, UTAH / ACCESS Newswire / February 27, 2025 / CenExel is pleased to announce its partnership with Metsera, Inc., a clinical-stage biopharmaceutical company dedicated to advancing treatm ...

At 2 years, participants in the compensated MASH cirrhosis treatment arm of the MAESTRO-NAFLD-1 trial experienced a ...

WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate ...

Full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million. Optune Lua® received FDA approval for the treatment of metastatic non-small cell lung ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment ...

Bayer presents positive results from phase III study QUANTI CNS of gadoquatrane at ECR 2025: Berlin Thursday, February 27, 2025, 14:00 Hrs [IST] Bayer, a global leader in radiolog ...

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (Stock Code: 1093.HK) jointly announced that the first patient has been successfully dosed in the Phase III ...

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Free Report) is anticipated to announce its earnings results before the market opens on Thursday, March 6th. Analysts expect the company to announce ...

Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET. Company Participants. Katie Hogan - Senior Director-Corporate Communications and Investo ...